Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21200560 | 0.81 | RBP4 (0.49) | RBP4ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2393871 | 0.78 | CYP1A2 (0.47) | ALDH1A1SMN1; SMN2MAPK1KDM4EGAA | |
| SCHEMBL18158113 | 0.78 | SORT1 (0.44) | RBP4ALDH1A1SMN1; SMN2TTRKDM4E | |
| SCHEMBL18924931 | 0.77 | ALOX15 (0.37) | RBP4ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL17542084 | 0.77 | MRGPRX4 (0.41) | RBP4ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL6120764 | 0.77 | ALOX15 (0.37) | RBP4ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL17542095 | 0.77 | TDP1 (0.60) | RBP4ALDH1A1MAPK1KDM4EALOX15 | |
| SCHEMBL11981453 | 0.77 | HSP90AA1 (0.46) | ALDH1A1KDM4ETSHR | |
| SCHEMBL23023554 | 0.77 | CBLB (0.45) | — | |
| SCHEMBL27894372 | 0.75 | RBP4 (0.35) | RBP4ALDH1A1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | claimed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-106715395-B | 6-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as TAAR modulators | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10316036-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3174853-B1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2015165085-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| CN-102985417-B | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORP | 2015-01-28 | — | — | CN | disclosed |
| CN-101379022-B | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE | 2013-05-01 | — | — | CN | disclosed |
| CN-102985417-A | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORP | 2013-03-20 | — | — | CN | disclosed |
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-7745477-B2 | Heteroaryl and benzyl amide compounds | HOFFMAN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| CN-101379022-A | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1984322-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | RBP4 2402/4885ALDH1A1 181/4885SMN1; SMN2 1381/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | RBP4 4053/4885ALDH1A1 986/4885SMN1; SMN2 3650/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | RBP4 3275/4885ALDH1A1 4576/4885SMN1; SMN2 2723/4885 |
| US-10316036-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HCRTR2, HCRTR1, CYP11B2 | RBP4 1680/4885ALDH1A1 352/4885SMN1; SMN2 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.